Evidence Synthesis Programme (ESP) is seeking to appoint a member to the Evidence Synthesis Programme Advisory Group (ESPAG).
Experienced representative from the NHS with a good understanding of evidence synthesis (Ref - ESP/21/02)
The Evidence Synthesis Programme (ESP) is seeking to appoint a member to the Evidence Synthesis Programme Advisory Group (ESPAG).
The Director of Science, Research and Evidence for the Department of Health and Social Care (DHSC) is looking to select an exceptional person to be the Programme Director of the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme, to succeed Professor Jo Rycroft-Malone who comes to the end of her tenure at the end of November 2021.
Specialist in Gastroenterology (Ref - EMEFC/21/02)
The Efficacy and Mechanism Evaluation (EME) programme is seeking to appoint members to the EME Funding Committee to replace those coming to the end of their tenure as well as to augment the breadth of expertise on the committee.
This opportunity is for a clinical academic with expertise in Gastroenterology and experience of clinical studies within the remit of the EME programme. Applications are particularly welcome from those with specialism in Hepatology.
The EME Programme supports clinical trials, and other robustly designed studies that test the efficacy of interventions, where there is sufficient evidence that the intervention might work in humans. Interventions should have the potential to improve patient care or benefit the public, and Innovative study designs involving stratification, the use of routinely collected digital data or novel methodologies are strongly encouraged. Where appropriate, the programme encourages hypothesis-testing mechanistic studies integrated within the main efficacy study. These studies could explore the mechanisms of action of the intervention, the causes of differing responses, or promote an understanding of any potential adverse effects and how these could be reduced; they could also contribute to understanding of the disease.
The programme also supports mechanistic studies that follow on from on-going or completed clinical studies, which can use data or samples from these studies. These can include qualitative research and opportunities for mechanistic work where the efficacy trial has not been successful. Please see our website page for more information about the programme remit.
The EME Funding Committee assesses Stage 1 and 2 proposals and makes funding recommendations to the EME Programme Director.
The term of office is 4 years starting in September 2021. The committee currently meets three times a year, but frequency of meetings may change, in consultation with the committee. Meetings are currently being run virtually. Going forward this format is likely to remain in effect. However, it is anticipated that there will be a limited requirement for face to face meetings in London, involving an overnight stay, approximately once per year.
The EME programme is jointly funded by the MRC (part of UK Research and Innovation) and NIHR. As such, there may be an opportunity for members to serve part of their tenure or support one of the other MRC translational scheme committees.
NIHR is committed to a supportive, inclusive, caring, and positive community. We warmly welcome those of different cultures, ages, ethnicities, and beliefs. Diversity and inclusion are fundamental to our values and vital to our success. We are currently looking to diversify and enrich our committees. We particularly welcome applications from disabled candidates and candidates from an ethnic minority background as they are currently under-represented.
If you have any questions about this opportunity please contact firstname.lastname@example.org.
You will find advice on how to apply in the guidance document linked below:
Applications close on Friday 23rd April 2021